AlzChem Group AG

XTRA:ACT Rapport sur les actions

Capitalisation boursière : €1.7b

AlzChem Group Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Andreas Niedermaier

Directeur général

€3.2m

Rémunération totale

Pourcentage du salaire du PDG10.98%
Durée du mandat du directeur général14.5yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction1.8yrs
Durée moyenne du mandat des membres du conseil d'administration13yrs

Mises à jour récentes de la gestion

Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

May 01
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

Recent updates

ACT: Specialty Platform And 2026 Expansions Will Underpin Cash Flow And Dividend Potential

Analysts have lifted their price targets on AlzChem to a range of about €195 to €197, reflecting updated models that incorporate a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally reduced future P/E. Analyst Commentary Recent research points to a broadly constructive stance on AlzChem Group, with several firms lifting price targets into a narrow band between about €195 and €197.

ACT: Specialty Platform And 2026 Expansions Will Support Measured Long Term Upside Potential

The updated analyst price target for AlzChem Group has moved from €165 to €173, as analysts point to recent target increases on the Street and renewed confidence in the company's specialty chemicals focus and niche production platform. Analyst Commentary Recent Street research has centered on higher price targets for AlzChem Group, with several firms highlighting the specialty chemicals profile and niche positioning as key supports for their views.

ACT: Specialty Chemicals Platform And 2026 Expansion Plans Will Support Upside

Analysts have lifted the implied fair value estimate for AlzChem Group to about €185 from roughly €177, supported by higher Street price targets in the €195 to €197 range and confidence in the company's specialty chemicals focus and production platform. Analyst Commentary Recent research updates point to a constructive tone from bullish analysts, who see the higher price targets as aligned with confidence in AlzChem Group's business model and execution around specialty chemicals.

ACT: Specialty Chemicals Moat And 2026 Projects Will Drive Future Upside

Narrative Update on AlzChem Group The analyst price target for AlzChem Group has moved from €185 to €195, with analysts highlighting the company's specialty chemicals performance, unique production platform and high margin growth projects as key factors in their updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on AlzChem Group, pointing to recent research updates as support for higher valuation expectations and confidence in the company’s execution.

ACT: New Creatine Capacity Plan Will Support Measured Long Term Upside Potential

Analysts are holding their price target for AlzChem Group steady at €165.00. They explain the unchanged view by pointing to updated assumptions that combine a slightly higher discount rate and P/E multiple with adjusted revenue growth and profit margin expectations.

ACT: New Creatine Investment Program Will Support Long Term Upside Potential

Analysts have lifted their price target on AlzChem Group from €150.00 to €165.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple in their models. What's in the News AlzChem Group AG has approved an investment program of around €120 million aimed at supporting additional profitable growth and reinforcing its presence in specialty chemicals for sports, food, and health (company announcement).

Is AlzChem Group AG (ETR:ACT) Trading At A 33% Discount?

Jan 23
Is AlzChem Group AG (ETR:ACT) Trading At A 33% Discount?

ACT: New Creatine Plant And 2025 Outlook Will Underpin Balanced Prospects

Analysts have modestly trimmed their price target for AlzChem Group to €176.94 from €179.93 as minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations feed into a slightly lower fair value estimate. What's in the News AlzChem Group AG approved an investment program of around €120 million to build a more automated production plant for creatine and its precursors, along with related infrastructure, targeting additional growth in sports, food and health (Key Developments).

ACT: New Creatine Capacity Expansion And 2025 Record Outlook Will Support Upside

Analysts now set a higher fair value target for AlzChem Group at €179.93 compared with €167.10 previously. They point to updated assumptions for revenue growth, profit margins and a lower future P/E multiple.

ACT: New Creatine Capacity And Partnerships Will Support Balanced Long Term Outlook

Analysts have raised their price target for AlzChem Group from €97.00 to €150.00, citing slightly stronger expectations for long term revenue growth and a higher justified future P E multiple, despite a modestly lower profit margin outlook. What's in the News AlzChem Group has approved an approximately EUR 120 million investment program to build a more automated creatine production plant and related infrastructure, targeting additional annual sales in the early triple-digit million euro range.

ACT: Earnings Guidance And New Product Launch Will Drive Record Performance

Analysts have maintained their price target for AlzChem Group at €167.10. They cite steady outlooks for revenue growth and profit margins, with only minor adjustments to the discount rate and future earnings projections.

AlzChem Group AG's (ETR:ACT) Business Is Trailing The Market But Its Shares Aren't

Nov 24
AlzChem Group AG's (ETR:ACT) Business Is Trailing The Market But Its Shares Aren't

ACT: Strong Revenue Outlook And Product Launches Will Drive Upside Momentum

Analysts have raised their price target for AlzChem Group from €163.10 to €167.10, citing improved revenue growth forecasts. These improved forecasts have offset slight adjustments in the discount rate and profit margin expectations.

ACT: Profitability Improvements And Product Launch Partnerships Will Support Fair Valuation

Analysts have raised their price target for AlzChem Group from €154.24 to €163.10. They cite improved profit margin projections and continued confidence in the company's financial outlook.

AlzChem Group AG (ETR:ACT) Shares Could Be 34% Below Their Intrinsic Value Estimate

Oct 13
AlzChem Group AG (ETR:ACT) Shares Could Be 34% Below Their Intrinsic Value Estimate

Is AlzChem Group (ETR:ACT) Using Too Much Debt?

Sep 13
Is AlzChem Group (ETR:ACT) Using Too Much Debt?

Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities

The increase in AlzChem Group’s consensus price target is primarily driven by a higher forward P/E multiple rather than changes in revenue growth forecasts, with fair value rising from €135.24 to €143.64. What's in the News AlzChem Group AG confirmed its full-year 2025 guidance, projecting organic sales growth of approximately 5% to around EUR 580 million.

Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

Aug 20
Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities

AlzChem Group's higher consensus price target reflects improved profitability and a lower forward P/E, indicating stronger earnings expectations and valuation support, with fair value raised from €124.40 to €135.24. What's in the News AlzChem Group AG confirmed full year 2025 guidance, expecting approximately 5% organic sales growth to around EUR 580 million.

AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 02
AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 22
AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)

Jun 02
Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)

A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)

May 19
A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)

What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You

May 05
What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

May 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?

May 01
Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Mar 28
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case

Mar 18
With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case

AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 05
AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Mar 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)

Feb 19
Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)
User avatar

Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position

Strategic expansion in production capacities and collaboration with the U.S. Department of Defense could bolster long-term revenue and market diversification.

AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point

Nov 14
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point

AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story

Oct 27
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story

When Should You Buy AlzChem Group AG (ETR:ACT)?

Oct 18
When Should You Buy AlzChem Group AG (ETR:ACT)?

AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

Sep 07
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

Jun 04
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

May 01
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 26
AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Is AlzChem Group (ETR:ACT) A Risky Investment?

Apr 11
Is AlzChem Group (ETR:ACT) A Risky Investment?

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Mar 07
The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Analyse de la rémunération des PDG

Comment la rémunération de Andreas Niedermaier a-t-elle évolué par rapport aux bénéfices de AlzChem Group?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2025n/an/a

€63m

Sep 30 2025n/an/a

€62m

Jun 30 2025n/an/a

€58m

Mar 31 2025n/an/a

€56m

Dec 31 2024€3m€350k

€54m

Sep 30 2024n/an/a

€50m

Jun 30 2024n/an/a

€46m

Mar 31 2024n/an/a

€39m

Dec 31 2023€2m€315k

€35m

Sep 30 2023n/an/a

€30m

Jun 30 2023n/an/a

€28m

Mar 31 2023n/an/a

€30m

Dec 31 2022€818k€315k

€30m

Sep 30 2022n/an/a

€29m

Jun 30 2022n/an/a

€28m

Mar 31 2022n/an/a

€27m

Dec 31 2021€890k€300k

€28m

Sep 30 2021n/an/a

€27m

Jun 30 2021n/an/a

€26m

Mar 31 2021n/an/a

€23m

Dec 31 2020€786k€300k

€20m

Sep 30 2020n/an/a

€16m

Jun 30 2020n/an/a

€17m

Mar 31 2020n/an/a

€17m

Dec 31 2019€915k€260k

€18m

Rémunération vs marché: La rémunération totale de Andreas ($USD 3.74M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.96M ).

Rémunération et revenus: La rémunération de Andreas a augmenté de plus de 20 % au cours de l'année écoulée.

PDG

Andreas Niedermaier (56 yo)

14.5yrs
Titularisation
€3,188,000
Compensation

Mr. Andreas Niedermaier has been Chairman of Executive Board & Chief Executive Officer at AlzChem Group AG since July 01, 2019 and has been its Member of Management Board since October 20, 2011. He served...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Andreas Niedermaier
CEO & Chairman of Executive Board14.5yrs€3.19mpas de données
Andreas Losler
CFO & Member of Management Board2.3yrs€1.45mpas de données
Martina Spitzer
Chief Sales Officer & Member of Management Board1.3yrspas de donnéespas de données
Jurgen Sans
COO & Member of Management Boardless than a yearpas de donnéespas de données
1.8yrs
Durée moyenne de l'emploi
53yo
Âge moyen

Gestion expérimentée: L'équipe de direction de ACT n'est pas considérée comme expérimentée (ancienneté moyenne 1.8 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Markus Zöllner
Independent Chairman of the Supervisory Board16.5yrs€42.00kpas de données
Martina Heigl-Murauer
Independent Member of the Supervisory Board9.4yrs€24.00kpas de données
Caspar von Schnurbein
Independent Deputy Chairman of the Supervisory Board9.4yrs€32.00kpas de données
Steve Röper
Independent Member of the Supervisory Board16.5yrs€22.00kpas de données
13.0yrs
Durée moyenne de l'emploi
54.5yo
Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la ACT est chevronné et expérimenté ( 13 années d'ancienneté moyenne).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/04/30 04:01
Cours de l'action en fin de journée2026/04/30 00:00
Les revenus2025/12/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

AlzChem Group AG est couverte par 7 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Volker BosseBaader Helvea Equity Research
Konstantin WiechertBaader Helvea Equity Research
Gerhard OrgonasBerenberg